Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival

被引：107

作者：

Casal-Mourino, Ana ^{[1
,2
]}

Ruano-Ravina, Alberto ^{[2
,3
]}

Lorenzo-Gonzalez, Maria ^{[2
,4
]}

Rodriguez-Martinez, Angeles ^{[2
,5
]}

Giraldo-Osorio, Alexandra ^{[2
,6
]}

Varela-Lema, Leonor ^{[2
,7
]}

Pereiro-Brea, Tara ^{[2
,8
]}

Barros-Dios, Juan Miguel ^{[2
]}

Valdes-Cuadrado, Luis ^{[1
,9
]}

Perez-Rios, Monica ^{[2
,3
]}

机构：

[1] Santiago De Compostela Univ, Clin Teaching Hosp, Dept Pneumol, Galicia, Spain

[2] Univ Santiago Compostela, Dept Prevent Med & Publ Hlth, La Coruna, Spain

[3] Consortium Biomed Res Epidemiol & Publ Hlth CIBER, Madrid, Spain

[4] Galician Reg Hlth Author, Populat Screening Unit, Santiago De Compostela, Spain

[5] Pontevedra Univ Hosp Complex, Dept Oncol, Pontevedra, Spain

[6] Univ Caldas, Dept Publ Hlth, Res Grp Hlth Promot & Dis Prevent, Manizales, Colombia

[7] Hlth Knowledge Management Agcy, Unidade Asesoramento Cient Tecn Avalia T, Galician Hlth Technol Assessment Agcy,Sci Tech Ad, Axencia Conecemento Saude ACIS,Galician Reg Hlth, Galicia, Spain

[8] A Coruna Univ Teaching Hosp Complex, Dept Pneumol, La Coruna, Spain

[9] Hlth Res Inst Santiago De Compostela IDIS, Interdisciplinary Grp Res Pulmonol, Santiago De Compostela, Spain

来源：

TRANSLATIONAL LUNG CANCER RESEARCH | 2021年 / 10卷 / 01期

关键词：

Lung cancer; staging; risk factors; histologic type; survival; incidence; CONCURRENT CHEMORADIOTHERAPY; CHECKPOINT-INHIBITORS; 8TH EDITION; PHASE-III; CELL; ADENOCARCINOMA; CARCINOMA; CHEMORADIATION; CONSOLIDATION; RADIOTHERAPY;

D O I：

10.21037/tlcr.2020.03.40

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Stage III non-small cell lung cancer (NSCLC) includes a highly heterogeneous group of patients with differences in the extent and localization of disease. Many aspects of stage III disease are controversial. The data supporting treatment approaches are often subject to a number of limitations, due to the heterogeneous patient populations involved in the trials. Furthermore, the definition of stage III disease has changed over time, and early studies were frequently inadequately powered to detect small differences in therapeutic outcome, were not randomized, or had a limited follow-up times. Major improvements in therapy, including the use of more active chemotherapy agents and refinements in radiation and surgical techniques, also limit the interpretation of earlier clinical trials. Lastly, improvements in pretreatment staging have led to reclassification of patients with relatively minimal metastatic disease as stage IV rather than stage III, leading to an apparent increase in the overall survival of both stage III and IV patients. Median overall stage III NSCLC survival ranges from 9 to 34 months. Higher survival rates are observed in younger Caucasian women with good performance status, adenocarcinoma, mutations, stage IIIA, and in patients with multidisciplinary-team-based diagnoses.

引用

页码：506 / 518

页数：13